Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer
Michael L. Beshiri(National Cancer Institute), Kathleen Kelly(National Cancer Institute), Crystal Tran(National Cancer Institute), Anson T. Ku(National Cancer Institute), William L. Dahut(National Cancer Institute), Caitlin M. Tice(National Cancer Institute), Danielle Burner(Duke University), Adam G. Sowalsky(National Cancer Institute), Ross Lake(National Cancer Institute), Fatima Karzai(National Institutes of Health), Brian J. Capaldo(University of Virginia), Samantha A. Morris(Brigham and Women's Hospital), Supreet Agarwal(University of Iowa), Aian Neil Alilin(National Cancer Institute), Tamara L. Lotan(Johns Hopkins University), Juan-Juan Yin(National Cancer Institute), Julianna Kostas(National Cancer Institute)
Cited by 6
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2023|592
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
|Clinical Cancer Research|2013|358